Dalteparin sodium
From Infogalactic: the planetary knowledge core
| Clinical data | |
|---|---|
| Trade names | Fragmin |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy category |
|
| Legal status |
|
| Routes of administration |
subcutaneous |
| Pharmacokinetic data | |
| Bioavailability | 81-93% |
| Biological half-life | 3-5 hours subcutaneous; 2.1-2.3 hours IV |
| Excretion | Renal |
| Identifiers | |
| CAS Number | 9041-08-1 |
| ATC code | B01AB04 (WHO) |
| DrugBank | DB06779 |
| KEGG | D03353 |
Dalteparin is a low molecular weight heparin. It is marketed as Fragmin by Pfizer Inc. Like other low molecular weight heparins, dalteparin is used for prophylaxis or treatment of deep vein thrombosis and pulmonary embolism. It is normally administered by self-injection.
The CLOT study, published in 2003, showed that in patients with malignancy and acute venous thromboembolism, dalteparin was more effective than warfarin in reducing the risk of recurrent embolic events.[1] Dalteparin is not superior to unfractionated heparin in preventing blood clots.[2]
Heparins are cleared by the kidneys, but studies have shown that dalteparin does not accumulate even if kidney function is reduced.[3]
